Search

Your search keyword '"Holowiecka, Aleksandra"' showing total 4 results
Start Over Author "Holowiecka, Aleksandra" Publication Year Range Last 10 years
4 results on '"Holowiecka, Aleksandra"'

1. Outcome of a Real-Life Population of Patients With Acute Promyelocytic Leukemia Treated According to the PETHEMA Guidelines: The Polish Adult Leukemia Group (PALG) Experience

Author

Sobas, Marta, Czyż, Anna, Montesinos, Pau, Armatys, Anna, Helbig, Grzegorz, Hołowiecka, Aleksandra, Pluta, Agnieszka, Zarzycka, Ewa, Piątkowska-Jakubas, Beata, Majcherek, Maciej, Lewandowski, Krzysztof, Gołos, Aleksandra, Paluszewska, Monika, Podhorecka, Monika, Oleksiuk, Jolanta, Skręt, Anna, Hawrylecka, Dorota, Guzicka-Kazimierczak, Renata Ewa, Wątek, Marzena, Gromek, Tomasz, Charliński, Grzegorz, Grosicki, Sebastian, Holojda, Jadwiga, Miśkiewicz, Wojciech, Martinez-Cuadrón, David, Sanz, Miguel Angel, Wróbel, Tomasz, Wierzbowska, Agnieszka, and Giebel, Sebastian

Published
2020
Full Text
View/download PDF

2. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Author

Labrador, Jorge, Luno, Elisa, Vellenga, Edo, Brunet, Salut, Gonzalez-Campose, Jose, Chillon, Maria C., Holowiecka, Aleksandra, Esteve, Jordi, Bergua, Juan, Gonzalez-Sanmiguel, Jose D., Gil, Cristina, Tormo, M., Salamero, Olga, Manso, Felix, Fernandez, Isolda, de laSerna, Javier, Moreno, Maria-Jose, Perez-Encinas, M., Krsnik, Isabel, Ribera, Josep-Maria, Cervera, Jose, Calasanz, Maria J., Boluda, Blanca, Sobas, Marta, Lowenberg, Bob, Sanz, Miguel A., Montesinos, Pau, Palmer, L., Fernandez, Ciarlo, S., Bezares, F., Rojas, F., Longoni, H., Gelemur, M., Fazio, P., Canepa, C., Saba, S., Balladares, G., Negri, P., Giunta, M., Milone, J., Prates, M., Lafalse, D., Sossa, C., Jaramillo, F., Mayer, J., Ramos, F., Martinez, J., de Groot, M. R., Schouten, H. C., Hematology, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), Interne Geneeskunde, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: MA Hematologie (9)

Subjects
Male, Cancer Research, complex karyotype, ANTHRACYCLINE MONOCHEMOTHERAPY, medicine.medical_treatment, Abnormal Karyotype, chemotherapy, Gastroenterology, Leukocyte Count, 0302 clinical medicine, Leukemia, Promyelocytic, Acute, Recurrence, Acute promyelocytic leukemia, Antineoplastic Combined Chemotherapy Protocols, PROGNOSTIC-SIGNIFICANCE, Cumulative incidence, ATRA, Child, In Situ Hybridization, Fluorescence, Aged, 80 and over, relapse, PETHEMA, Incidence (epidemiology), ADDITIONAL CHROMOSOME-ABNORMALITIES, Age Factors, Hematology, Middle Aged, Prognosis, ARSENIC TRIOXIDE, FLT3 MUTATIONS, Leukemia, Treatment Outcome, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Cytogenetic Analysis, Female, Adult, medicine.medical_specialty, CYTOGENETIC CHANGES, Adolescent, Young Adult, 03 medical and health sciences, Internal medicine, Statistical significance, Complex Karyotype, medicine, Humans, Clinical significance, Aged, CONSOLIDATION THERAPY, Chromosome Aberrations, Chemotherapy, business.industry, medicine.disease, RISK-ADAPTED TREATMENT, TRANS-RETINOIC ACID, ATRA, Acute promyelocytic leukemia, chemotherapy, complex karyotype, prognostic, relapse, business, prognostic, 030215 immunology
Abstract

Although additional cytogenetic abnormalities (ACA) do not affect the prognosis of patients with t(15;17) acute promyelocytic leukemia (APL), the role of a complex karyotype (CK) is yet to be clarified. We aimed to investigate the relationship of CK with relapse incidence in 1559 consecutive APL patients enrolled in three consecutive trials. Treatment consisted of AIDA induction followed by risk-adapted consolidation. A CK (CK) was defined as the presence of ≥2 ACA, and a very CK (CK+) as ≥3 ACA. Eighty-nine patients (8%) had a CK, of whom 41 (4%) had CK+. The 5-year cumulative incidence of relapse (CIR) in patients with CK was 18%, and 12% in those with

Published
2019

3. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

Author

Sobas, Marta, Montesinos, Pau, Boluda, Blanca, Bernal, Teresa, Vellenga, Edo, Nomdedeu, Josep, Gonzalez-Campos, Jose, Chillon, Maria, Holowiecka, Aleksandra, Esteve, Jordi, Bergua, Juan, David Gonzalez-Sanmiguel, Jose, Gil-Cortes, Cristina, Tormo, M., Salamero, Olga, Manso, Felix, Fernandez, Isolda, de la Serna, Javier, Moreno, Maria-Jose, Perez-Encinas, Manuel, Krsnik, Isabel, Ribera, Josep-Maria, Escoda, Lourdes, Lowenberg, Bob, Angel Sanz, Miguel, Beltran de Heredia, J. M., Hernandez, J. M., Arias, J., Ramos, F., Roman, A., de la Serna, J., Negri, S., Rayon, C., Esteve, J., Fernandez-Calvo, F. J., Diaz-Mediavilla, J., Gil, C., Olave, M., Amutio, E., Pedro, C., Gorosquieta, A., Viguria, M., Zudaire, M., Molero, T., Sayas, M. J., Guardia, R., Martinez, J., de Groot, M. R., Schouten, H. C., Hematology, Radiotherapy, Erasmus MC other, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Stem Cell Aging Leukemia and Lymphoma (SALL), Interne Geneeskunde, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: MA Hematologie (9)

Subjects
Male, Cancer Research, medicine.medical_treatment, Retinoic acid, CD34, Gene Expression, Kaplan-Meier Estimate, chemotherapy, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, PROGNOSTIC-FACTORS, Leukemia, Promyelocytic, Acute, Recurrence, Acute promyelocytic leukemia, Antineoplastic Combined Chemotherapy Protocols, FAILURE, Anthracyclines, Cumulative incidence, ATRA, Child, CONSOLIDATION, relapse, RISK, Hematology, Middle Aged, Prognosis, CD56 Antigen, Leukemia, Treatment Outcome, Oncology, Child, Preschool, 030220 oncology & carcinogenesis, Female, CD56, medicine.medical_specialty, Adolescent, Anthracycline, Tretinoin, Young Adult, 03 medical and health sciences, ADULT, Internal medicine, medicine, Humans, INDICATOR, Aged, Chemotherapy, business.industry, De novo acute, medicine.disease, chemistry, business, prognostic, 030215 immunology
Abstract

Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL presented higher induction death rate (16% vs 8%, p = .02) and 5-years cumulative incidence of relapse (33% versus 10%, p = .006), irrespectively of the Sanz score (low-risk 47% versus 5%, p

Published
2019
Full Text
View/download PDF

4. Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy

Author

Labrador, Jorge, primary, Luño, Elisa, additional, Vellenga, Edo, additional, Brunet, Salut, additional, González-Campos, José, additional, Chillón, Maria C., additional, Holowiecka, Aleksandra, additional, Esteve, Jordi, additional, Bergua, Juan, additional, González-Sanmiguel, José D, additional, Gil, Cristina, additional, Tormo, Mar, additional, Salamero, Olga, additional, Manso, Felix, additional, Fernández, Isolda, additional, de laSerna, Javier, additional, Moreno, María-José, additional, Pérez-Encinas, Manuel, additional, Krsnik, Isabel, additional, Ribera, Josep-Maria, additional, Cervera, Jose, additional, Calasanz, María J., additional, Boluda, Blanca, additional, Sobas, Marta, additional, Lowenberg, Bob, additional, Sanz, Miguel A., additional, and Montesinos, Pau, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results